Abstract
Magnetic resonance (MR) multimodality evoked potentials (MEPs) and clinical findings were correlated in a 47-year-old epileptic man in whom parenteral valproic acid (VPA) therapy induced severe comatose hyperammonemic encephalopathy without biological signs of hepatotoxicity (or hepatocytic dysfunction). Although the plasma VPA level remained within a normal therapeutic range, the ammoniemia increased to a toxic peak level at 411 μmol/l 24 h after symptom onset, requiring VPA therapy discontinuation. Brain MR monitoring demonstrated early cytotoxic edema evolving into delayed vasogenic edema and final brain atrophy. Concomitantly to abnormalities within the brainstem on MR images, an increase in brainstem conduction at MEPs and clinical disturbance of brainstem reflexes were observed at the initial phase of the disease course. Later, the resolution of the MR and MEPs abnormalities paralleled the clinical recovery of the reflexes.
This is a preview of subscription content, log in via an institution to check access.
References
Altunbasak S, Baytok V, Tasouji M et al (1997) Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol 12:461–463
Lee WL, Yang CC, Deng JF, Chen YF, Lin HD, Wang PH (1998) A case of severe hyperammonemia and unconsciousness following sodium valproate intoxication. Vet Hum Toxicol 40:346–348
Barrueto F Jr, Hack JB (2001) Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med 8:999–1001
Feil D, Chuang K, Sultzer DL (2002) Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry 10:476–478
Spiller HA, Krenzelok EP, Klein-Schwartz W et al (2000) Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 38:755–760
Duarte J, Macias S, Coria F, Fernandez E, Claveria LE (1993) Valproate-induced coma: case report and review of the literature. Ann Pharmacother 27:582–583
Guérit JM, de Tourtchaninoff M, Soveges L, Mahieu P (1993) The prognostic value of three-modality evoked potentials (TMEPs) in anoxic and traumatic comas. Neurophysiol Clin 23:209–226
Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40:789–801
Ratnaike RN, Schapel GJ, Purdie G, Rischbieth RH, Hoffmann S (1986) Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 22:100–103
Hamer HM, Knake S, Schomburg U, Rosenow F (2000) Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54:230–232
Dupuis RE, Lichtman SN, Pollack GM (1990) Acute valproic acid overdose: clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf 5:65–71
Khoo SH, Leyland MJ (1992) Cerebral edema following acute sodium valproate overdose. J Toxicol Clin Toxicol 30:209–214
Triggs WJ, Gilmore RL, Millington DS, Cibula J, Bunch TS, Harman E (1997) Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Int J Clin Pharmacol Ther 35:353–356
Baganz MD, Dross PE (1994) Valproic acid-induced hyperammonemic encephalopathy: MR appearance. Am J Neuroradiol 15:1779–1781
Ziyeh S, Thiel T, Spreer J, Klisch J, Schumacher M (2002) Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia 43:1101–1105
Schaefer PW, Grant PE, Gonzalez RG (2000) Diffusion-weighted MR imaging of the brain. Radiology 217:331–345
Wieshmann UC, Symms MR, Shorvon SD (1997) Diffusion changes in status epilepticus. Lancet 350:493–494
Collins RM Jr, Zielke HR, Woody RC (1994) Valproate increases glutaminase and decreases glutamine synthetase activities in primary cultures of rat brain astrocytes. J Neurochem 62:1137–1143
Blindauer KA, Harrigton G, Morris GL III, Ho KC (1998) Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 51:292–295
Rovira A, Cordoba J, Raguer N, Alonso J (2002) Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation. Curr Opin Neurol 15:731–737
Dolman CL, Clasen RA, Dorovini-Zis K (1988) Severe cerebral damage in ornithine transcarbamylase deficiency. Clin Neuropathol 7:10–15
Mirowitz SA, Saitor K, Prensky AJ, Gado M, Hodges FJ (1991) Neurodegenerative diseases of childhood: MR and CT evaluation. J Comput Assist Tomogr 15:210
Mamourian AC, du Plessis A (1991) Urea cycle defect: a case with MR and CT findings resembling infarct. Pediatr Radiol 21:594–595
Takanashi J, Barkovich J, Cheng S, Kostiner D, Baker J, Packman S (2003) Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. Am J Neuroradiol 24:390–393
Chen YF, Huang YC, Liu HM, Hwu WL (2001) MRI in a case of adult-onset citrullinemia. Neuroradiology 43:845–847
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hantson, P., Grandin, C., Duprez, T. et al. Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma. Eur Radiol 15, 59–64 (2005). https://doi.org/10.1007/s00330-004-2338-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-004-2338-9